A Phase 4 interventional study of Romosozumab and Denosumab Combination Therapy and Romosozumab Prefilled Syringe [Evenity] in Osteoporosis in Post-menopausal Women, sponsored by Marmara University. Not yet recruiting at 1 site in Turkey. Open to female participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Marmara University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.
Among the 20 studies testing romosozumab in Osteoporosis, this one is the 13th largest by planned enrollment, is one of 2 that started in 2025, is one of 10 in phase 4, and was the 17th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
University of Aarhus · Sites in Denmark
Ages 50+ · Women only
Sahlgrenska University Hospital · Sites in Sweden
Ages 60+ · Women only
Tuen Mun Hospital · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 60 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 80 across the 20 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Marmara University is the lead sponsor of 601 studies on the registry; 137 are open to participants now.
Marmara University has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing romosozumab in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05775094Memorial Sloan Kettering Cancer CenterA Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | 2027-03 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07757373Tuen Mun HospitalRomosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing romosozumab in Osteoporosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to investigate the effectiveness of romosozumab started without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures and who is under at least 2 years of denosumab treatment. The main questions aimed to answer are:
Researchers will compare the Romosozumab 210mg subcutaneous(sc) monthly plus denosumab 60mg per 6 months sc treatment to prooceeding denosumab treatment and romosozumab 210mg monthly treatment in patient whom denosumab cessaced.
Participians are postmenopousal women with osteoporosis and they are under at least 2 years of treatment with denosumab and they will:
Osteoporosis, whether accompanied by low bone resorption, microarchitectural deterioration, and fragility, leads to poor bone strength and increased risk of fracture. Decreased bone strength can also be due to external factors including bone formation and resorption (turnover), bone geometry (bone size and shape), and bone mineral density (BMD), including microarchitecture. Osteoporotic fractures lead to a significant decrease in quality of life with increased morbidity, mortality, and disability. More than 50 percent of postmenopausal white women will have an osteoporotic fracture, and only 33 percent of older women with a hip fracture are able to live independently.
The World Health Organization (WHO) has defined diagnostic thresholds for low bone density and osteoporosis based on measurements of bone density versus the young adult reference (T score). Postmenopausal women with osteoporosis have decreased bone loss and/or experienced associated bone loss.
Romosozumab is a drug used to treat osteoporosis. Romosozumab is an FDA-cleared humanized monoclonal antibody sclerostin inhibitor used to treat postmenopausal osteoporosis at high risk of fracture, including patients with a history of osteoporotic fractures, those who have failed or are tolerant to other available osteoporosis therapies, and those who have failed or are tolerant to other available osteoporosis therapies. It increases bone formation and impairs bone resorption.
For most postmenopausal women with osteoporosis, oral bisphosphonates are preferred as initial therapy because of their efficacy, affordability, and availability of long-term safety data. Treatment selection should be based on efficacy, safety, cost, freedom, and the individual's fracture risk.
In a 2019 meta-analysis of 107 studies evaluating pharmacological treatments in postmenopausal women with osteoporosis, alendronate, zoledronic acid, risdronate, denosumab, romosozumab, and estrogen with progestin were found to reduce the risk of hip fractures. Alendronate, zoledronic acid, rosedronate, ibandronate, denosumab, abaloparatide, teriparatide, parathyroid hormone (1.84), romosozumab, raloxifene, bazedoxifene, lasofoxifene, estrogen with progestin, tibolone, and calcitonin were found to reduce the risk of vertebral fractures. Anabolic agents (teriparatide, abaloparatide, romosozumab) and denosumab were found to have the highest relative efficacy, but few studies compared the drugs in terms of fracture prevention.
Current evidence suggests that Romosozumab therapy is a good option for osteoporosis in postmenopausal women with a history of multiple fractures and BMD measurements below L1-L4 or Femoral Neck T-scores below -3.5. The anabolic agent romosozumab uniquely stimulates bone formation and inhibits bone resorption. In postmenopausal women at very high risk of fracture, literature data suggests that anabolic therapies prevent fractures to a greater extent compared with oral bisphosphonates. Romosozumab induces a greater BMD response than abaloparatide or teriparatide, but clinical experience is limited and long-term side effects are uncertain.
In Lancet's systematic review of osteoporosis treatment, it was recommended that long-term follow-up, fracture outcome studies be conducted to evaluate the effectiveness of combined treatments in patients with high fracture risk.
Combination therapies refer to the sequential or simultaneous administration of two drugs. In the previous ARCH study, a better treatment response was seen in the group given 70mg/week alendronate after 12 months of 210mg/month romosozumab treatment compared to the group given 70mg/week alendronate alone. In the FRAME study, new fractures were significantly less in the group given 12 months of 60mg/6month denosumab after 12 months of 210mg/month romosozumab treatment compared to the group given 12 months of 60mg/6month denosumab after 12 months of placebo. These two studies were phase 3 studies that demonstrated the efficacy of sequential therapies and romosozumab in the treatment of osteoporosis.
In the DATA-Switch study published in Lancet in 2015, which evaluated the combination and sequential treatments of teriparatide and denosumab, 3 groups were formed with a total of 48 months of sequential 24-month treatments, and these groups were given Denosumab after Teriparatide; Teriparatide after Denosumab and Denosumab after the combination of these two drugs. The results of the study showed that teriparatide after denosumab did not prevent sufficient fracture risk and did not provide sufficient improvement in BMD measurements, in line with the literature. In addition, the use of denosumab was found to be more appropriate both after combined treatment and after teriparatide alone. The best BMD improvement was determined in the group that received denosumab after combined treatment.
In a study conducted by McClung et al., the study included patients who were in the placebo group in the first 24 months of the Romosozumab Phase 2 study (NCT00896532) and were randomized to placebo or denosumab for the next 12 months. In this phase 2 study, 210 mg/month romosozumab was finally administered to all study arms. The study results showed that romosozumab at least maintains BMD improvement after denosumab, while it is more effective in naïve patients. The STRUCTURE phase 2 extension study also showed that romosozumab provided minimal BMD improvement in the patient group who received a second course of 12-month romosozumab treatment after denosumab. In this context, it is possible to say that romosozumab is more effective in naive patients, but this situation brings to mind the problem that like the use of teriparatide alone after denosumab is not appropriate the use of romosozumab after denosumab may decrease its effectiveness, and may not be appropriate in terms of effectiveness and cost, even if it does not worsen the disease. IIn a case written by Kashii et al. in 2020, the patient who applied after missing his follow-up for 3 months had 9 months since his last denosumab dose at the time of application. Although there was no new fracture development, the patient was switched to romosozumab treatment because sufficient BMD improvement could not be detected with denosumab. The patient, who did not have back pain complaints at the time of the transition and in the 1st month, had back pain complaints at the 3rd month follow-up, but no fracture was detected in the direct radiography performed on the patient and MRI could not be performed due to the patient's claustrophobia. In the direct radiography taken in the 4th month of romosozumab, a total of 5 new fractures at the thoracic and lumbar levels were detected. Although romosozumab treatment was completed in the 6th month of this case, sufficient improvement was not detected in BMD measurements. In a case written by Krikelis et al., denosumab was stopped and romosozumab was started in a patient who developed 1 vertebral fracture under denosumab. 5 new thoracic and lumbar vertebral fractures were detected in the 6th month of romosozumab treatment. This situation was attributed to the withdrawal effect of denosumab, and romosozumab was discontinued and denosumab was started again. After 1 month, the patient's back pain regressed. At this point, due to insufficient literature, they considered adding denosumab again while continuing romosozumab, but they could not do it. Two published cases in this treatment regimen and literature data on the use of teriparatide after denosumab show us that the effect of adding romosozumab should be investigated while continuing denosumab treatment, especially in patients with a high risk of rebound-related vertebral fractures, when anabolic agent treatment is planned.
In a study conducted by Adami et al., which is the only example in the literature on combined treatment with Romosozumab and Denosumab, romosozumab was started in drug-naive patients in the first of the 3 study arms, romosozumab was added to the group that had been using denosumab for over 2 years in the second group, and denosumab treatment was continued alone in the last group. After 6 months of follow-up, romosozumab administered to naive patients was found to be superior to other treatments in reducing the risk of hip fractures, while similar results were found with combined treatment in reducing the risk of lumbar fractures. IIn the group where denosumab was continued alone, the reduction in fracture risk was found to be significantly less than in the other groups. This study did not include information on side effects and complications.
It is obvious that there is a lack of information in the literature on the treatment arrangement without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures, when it is planned to switch to romosozumab after denosumab. At this point, a study should be planned on this subject. The aim of our study is to investigate the effectiveness of romosozumab, which is started without stopping denosumab, and therefore the effectiveness of romosozumab-denosumab combined treatment in patients with postmenopausal osteoporosis diagnosed with a very high risk of fragility fractures and receiving denosumab treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Romosozumab 210 mg subcutaneously per month combined with denosumab 60mg subcutaneously per 6 months
Drug: Romosozumab and Denosumab Combination Therapy
Romosozumab 210 mg subcutaneously per month
Drug: Romosozumab Prefilled Syringe [Evenity]
denosumab 60mg subcutaneously per 6 months
Drug: Denosumab (Prolia)
Drug pages: RomosozumabStudies of RomosozumabRomosozumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Romosozumab 210mg per month and denosumab 60mg per 6 months will be applied
Romosozumab 210mg subcutaneously per month
Denosumab 60 mg subcutaneously per 6 months
New Fracture
If the patient exposed new fracture along treatment period
Time frame: 1 year and 9 months
Bone Mineral Density
Bone mineral density before treatment regimen and after treatment done
Time frame: 1 year
New fracture at long term follow up
If the patient exposed new fracture along long term follow up (Phase 2 of this study) period
Time frame: 5 years
Beta Crosslaps
Beta Crosslaps value througout treatment regimen per 6 months interval
Time frame: 6 months interval
Plan to share: Undecided
Start is estimated for Jan 2025; primary completion for Oct 2026, 21 months later.
Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 21 months is below that.
Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Romosozumab · Denosumab